Frank Mathias to become CEO of Rentschler Biotechnologie

Nikolaus Rentschler joins supervisory board to concentrate on further expansion of the Rentschler Group

Rentschler Biotechnologie, a German contract manufacturing organisation, announces the appointment of Frank Mathias as Chief Executive Officer (CEO), effective 1 April. Mathias had previously been a member of the supervisory board at Rentschler.

Former CEO, Nikolaus Rentschler, is moving to the supervisory board to concentrate on the further expansion of the Rentschler Group, the firm said.

Mathias studied pharmacy at the Paris VI University where he graduated in 1991. He has gained more than 25 years’ experience in leading positions in the pharmaceutical and biotech industry. His industrial career began when he became International Product Manager at Hoechst. After that, he became CEO of Servier Deutschland and Amgen Deutschland.

In 2009 he became CEO at Medigene, where he was responsible for Marketing, Sales and Business Development. Since then, the company has developed further in the area of immuno-oncology.

As Chairman of vfa-bio, the stakeholder of biotechnology within vfa research-based pharmaceutical companies, Mathias also has good contacts within the pharmaceutical and biotech industry, the firm said.

Companies